Tier 2 — strong
Can acetylcysteine ameliorate cisplatin-induced toxicities and oxidative stress without decreasing antitumor efficacy? A randomized, double-blind, placebo-controlled trial involving patients with head and neck cancer
Cancer Med
2019
8(5):2020-2030
Bibliography
- PubMed
- PMID 30977273
- PubMed Central
- PMC6536930
- Funding
- Funding disclosure was not located in the indexed record reviewed; consult the source publication for the full funding statement.
- Competing interests
- Competing-interest disclosure was not located in the indexed record reviewed; consult the source publication for the full declaration.
Study snapshot
| Design | Randomized double-blind placebo-controlled trial |
|---|---|
| Model | Human |
| Sample | 57 patients with head and neck cancer |
| Intervention | Oral NAC around high-dose cisplatin chemotherapy versus placebo |
| Duration | During cisplatin treatment cycles |
| Endpoints | Cisplatin toxicities; Oxidative stress; Tumor response |
What the study showed, in plain terms
Key findings
What this study can and cannot tell us
Editorial review
Reviewed by the Biohack Blueprint research team
Last verified



